## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%); PEG 1.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($245.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Coho Partners Ltd. Sells 16,120 Shares of STERIS plc $STE**
- Source: MarketBeat | 20251223T094626 | Bullish | Relevance: 100%
- Coho Partners Ltd. has reduced its stake in STERIS plc by 13.1%, selling 16,120 shares and now owning 106,865 shares worth approximately $26.44 million. Other institutional investors have also adjusted their positions in STERIS. Several insiders recently sold a significant number of shares, while Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $273.50.

**2. Congress Asset Management Co. Raises Stock Holdings in STERIS plc $STE**
- Source: MarketBeat | 20251222T090453 | Somewhat-Bullish | Relevance: 100%
- Congress Asset Management Co. has increased its stake in STERIS plc (NYSE:STE) by 8.4% in the third quarter, now owning 133,224 shares valued at $32.965 million. Other institutional investors have also adjusted their positions in the medical equipment provider. STERIS announced a quarterly dividend of $0.63 per share, with recent insider selling activity, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $273.50.

**3. STERIS plc $STE Shares Bought by Foster Victor Wealth Advisors LLC**
- Source: MarketBeat | 20251221T120121 | Bullish | Relevance: 100%
- Foster Victor Wealth Advisors LLC significantly increased its stake in STERIS plc (NYSE:STE), acquiring an additional 4,646 shares and bringing their total to 80,029 shares valued at $19.41 million. This makes STERIS the 21st largest holding in their portfolio, representing about 1.2% of their investments. The medical equipment provider also delivered strong Q3 results, beating analyst expectations with $2.47 EPS and $1.46 billion in revenue, and announced a quarterly dividend of $0.63 per share.

**4. CooperCompanies appoints Walt Rosebrough to board in deal with Browning West**
- Source: Investing.com India | 20251223T132751 | Somewhat-Bullish | Relevance: 74%
- CooperCompanies (NASDAQ:COO) has appointed Walter "Walt" M. Rosebrough, Jr. as an independent director, effective January 3, 2026, following a cooperation agreement with Browning West, LP. Rosebrough, CEO Emeritus of STERIS plc, will join the Corporate Governance & Nominating Committee, with consideration for him to become Chair by the end of 2026. This move comes as CooperCompanies' stock has gained 20.6% over the past six months, reflecting recent financial outperformances and positive analyst revisions.

**5. Former Steris CEO takes board role at California medical device company**
- Source: Crain's Cleveland Business | 20251223T180741 | Somewhat-Bullish | Relevance: 72%
- Walter M. Rosebrough Jr., former CEO of Steris plc, has been appointed as an independent director at CooperCompanies (Nasdaq: COO), a California-based medical device company. This appointment follows a cooperation agreement with activist investor Browning West LP, which urged changes due to alleged underperformance. Rosebrough is also being considered for the board chair position by the end of 2026, and his proven track record is expected to enhance long-term shareholder value.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.73 elevated, pricing in significant growth expectations. Forward P/E 22.9x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.73 |
| Forward P/E | 22.9 |
| Current P/E | 25.0 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.0% to -0.7% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-0.78), momentum weakening. RSI neutral at 49. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.72% (CS: 55) | Neutral |
| RSI_14 | 49.2 | Neutral |
| MACD Histogram | -0.78 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 1.065x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $255.28
- **Stop Loss:** $245.56 (3.8% risk)
- **Target:** $265.00 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 123
- **Position Value:** $31,399.44
- **Portfolio %:** 31.40%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*